Skip to main content
. 2019 May 28;74(8):1480–1489. doi: 10.1111/all.13842

Figure 1.

Figure 1

Trial design. ACC, allergen challenge chamber; AIT, allergen immunotherapy; TU, therapeutic units. Subcutaneous injections (upper arm) were administered first at dose escalation steps of 7 d (100, 200, 400, 800, 1500, 3000, and 6000 TU); the maintenance dose of 6000 TU was then administered after 2 wk, and then after 4 wk and finally extended to intervals of 6‐8 wk